For research use only. Not for therapeutic Use.
Enasidenib(CAT: I001718) is a selective, oral inhibitor of isocitrate dehydrogenase 2 (IDH2), an enzyme involved in cellular metabolism. Mutations in IDH2 result in the abnormal production of 2-hydroxyglutarate (2-HG), an oncometabolite that contributes to impaired cellular differentiation and tumor growth. By inhibiting mutant IDH2, Enasidenib reduces 2-HG levels, promoting the differentiation of malignant cells. It is primarily used in the treatment of relapsed or refractory acute myeloid leukemia (AML) with IDH2 mutations. Enasidenib plays a significant role in oncology research, particularly in developing targeted therapies for hematologic malignancies driven by metabolic dysregulation.
| CAS Number | 1446502-11-9 |
| Synonyms | 2-methyl-1-((4-(6-(trifluoromethyl)pyridin-2-yl)-6-((2-(trifluoromethyl)pyridin-4-yl)amino)-1,3,5-triazin-2-yl)amino)propan-2-ol |
| Molecular Formula | C₁₉H₁₇F₆N₇O |
| Purity | ≥95% |
| Target | Isocitrate Dehydrogenase (IDH) |
| Solubility | 10 mM in DMSO |
| Storage | Store at -20°C |
| IUPAC Name | 2-methyl-1-[[4-[6-(trifluoromethyl)pyridin-2-yl]-6-[[2-(trifluoromethyl)pyridin-4-yl]amino]-1,3,5-triazin-2-yl]amino]propan-2-ol |
| InChI | InChI=1S/C19H17F6N7O/c1-17(2,33)9-27-15-30-14(11-4-3-5-12(29-11)18(20,21)22)31-16(32-15)28-10-6-7-26-13(8-10)19(23,24)25/h3-8,33H,9H2,1-2H3,(H2,26,27,28,30,31,32) |
| InChIKey | DYLUUSLLRIQKOE-UHFFFAOYSA-N |
| SMILES | CC(C)(CNC1=NC(=NC(=N1)NC2=CC(=NC=C2)C(F)(F)F)C3=NC(=CC=C3)C(F)(F)F)O |
